Mark DeWitte

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

Michelle Harrison, Eva Obermueller, Nick Maisey et al. · Journal of Clinical Oncology · 2007 · 248 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study

Anthony W. Tolcher, Leonel Ochoa, Lisa A. Hammond et al. · Journal of Clinical Oncology · 2003 · 205 citations

Pharmacy, Oncology, Pharmacology +17

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer

Ewan Brown, Kellie A. Charles, Susan Hoare et al. · Annals of Oncology · 2008 · 182 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.

Bertram Wiedenmann, Peter Malfertheiner, Helmut Friess et al. · PubMed · 2008 · 144 citations

Medicine, Oncology, Pharmacotherapy +16

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Simon He, Samantha J. Busfield, Mark Hertzberg et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 124 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16